Home > Boards > US Listed > Medical - Drugs > Abbvie (ABBV)

ABBV 3Q18 results (from 11/2/18):

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 720
Posts 108,437
Boards Moderated 22
Alias Born 09/05/02
160x600 placeholder
AbbVie Nears Deal to Buy Allergan for More Than $60 Billion--2nd Update Dow Jones News - 6/25/2019 7:34:00 AM
AbbVie Nears Deal to Buy Allergan for More Than $60 Billion--Update Dow Jones News - 6/25/2019 7:02:00 AM
AbbVie Nears Deal to Buy Allergan for More Than $60 Billion Dow Jones News - 6/25/2019 6:56:00 AM
AbbVie to Acquire Allergan in Transformative Move for Both Companies PR Newswire (US) - 6/25/2019 6:42:00 AM
AbbVie Says FDA Lifts Partial Hold on Phase 3 Trial Dow Jones News - 6/24/2019 9:38:00 AM
AbbVie Announces US FDA Lifts Partial Clinical Hold on Phase 3 Study of Venetoclax in Patients with Multiple Myeloma Positive... PR Newswire (US) - 6/24/2019 8:45:00 AM
AbbVie Declares Quarterly Dividend PR Newswire (US) - 6/20/2019 1:45:00 PM
Annual Report of Employee Stock Plans (11-k) Edgar (US Regulatory) - 6/18/2019 5:01:38 PM
New Long-Term Data from Upadacitinib Phase 3 Studies in Rheumatoid Arthritis Including Results on Clinical Remission at 48 We... PR Newswire (US) - 6/12/2019 6:00:00 PM
New Two-Year Data at the 24th World Congress of Dermatology Shows SKYRIZI™ (risankizumab) Maintains Complete Skin Clearance PR Newswire (US) - 6/11/2019 7:00:00 AM
AbbVie's MAVIRET™ now listed on the Nova Scotia and Manitoba formularies PR Newswire (Canada) - 6/10/2019 8:00:00 AM
AbbVie to Present at the Goldman Sachs Global Healthcare Conference PR Newswire (US) - 6/7/2019 8:00:00 AM
AbbVie reçoit une recommandation favorable du Comité d'experts en examen du Programme pancanadien d'évaluation des antican... PR Newswire (Canada) - 6/6/2019 9:00:00 AM
AbbVie Receives Positive Recommendation from the pan-Canadian Oncology Drug Review Expert Review Committee for the Combinatio... PR Newswire (Canada) - 6/6/2019 9:00:00 AM
AbbVie Presents Data from Venetoclax Chemotherapy-Free Combination Regimen for Patients with Previously Untreated Chronic Lym... PR Newswire (US) - 6/4/2019 11:09:00 AM
Specialized Disclosure Report (sd) Edgar (US Regulatory) - 5/31/2019 5:01:56 PM
AbbVie Presents Results from Several Studies and Clinical Trials Investigating Medicines Across More than 15 Cancers at the 2... PR Newswire (US) - 5/30/2019 8:45:00 AM
MAVIRET(MC) d'AbbVie maintenant inscrit sur la liste des médicaments du Nouveau-Brunswick PR Newswire (Canada) - 5/30/2019 8:00:00 AM
AbbVie's MAVIRET™ now listed in New Brunswick PR Newswire (Canada) - 5/30/2019 8:00:00 AM
Johnson & Johnson Weighs on Pharmaceutical ETFs Dow Jones News - 5/29/2019 2:30:00 PM
AbbVie conclut une entente avec l'Alliance pancanadienne pharmaceutique (APP) concernant VENCLEXTA®, un traitement de la leu... PR Newswire (Canada) - 5/23/2019 9:00:00 AM
AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for VENCLEXTA®, a treatment for chronic lym... PR Newswire (Canada) - 5/23/2019 9:00:00 AM
AbbVie met sur le marché la dose d'ORILISSA(MC) (élagolix) à 200 mg deux fois par jour pour le traitement des douleurs mod... PR Newswire (Canada) - 5/21/2019 8:00:00 AM
AbbVie Launches ORILISSA™ (elagolix) 200 mg BID Dose for the Treatment of Moderate to Severe Pain Associated with Endometri... PR Newswire (Canada) - 5/21/2019 8:00:00 AM
AbbVie Glioblastoma Drug Misses Primary Endpoint Dow Jones News - 5/17/2019 9:31:00 AM
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist